524 related articles for article (PubMed ID: 15600379)
1. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Shelton CI
J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
[TBL] [Abstract][Full Text] [Related]
2. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
3. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
[TBL] [Abstract][Full Text] [Related]
4. SNRIs in the management of acute major depressive disorder.
Zajecka JM; Albano D
J Clin Psychiatry; 2004; 65 Suppl 17():11-8. PubMed ID: 15600377
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
6. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
7. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
8. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
de Silva VA; Hanwella R
Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
[TBL] [Abstract][Full Text] [Related]
10. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
[TBL] [Abstract][Full Text] [Related]
11. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
13. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
Thase ME; Entsuah AR; Rudolph RL
Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
[TBL] [Abstract][Full Text] [Related]
14. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
15. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
Dell'Osso B; Nestadt G; Allen A; Hollander E
J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
17. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
Machado M; Iskedjian M; Ruiz I; Einarson TR
Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
[TBL] [Abstract][Full Text] [Related]
18. Are SNRIs more effective than SSRIs? A review of the current state of the controversy.
Thase ME
Psychopharmacol Bull; 2008; 41(2):58-85. PubMed ID: 18668017
[TBL] [Abstract][Full Text] [Related]
19. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]